Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer

Journal of Surgical Oncology

Volumn 108, Issue 2, 2013, Pages 113-120

  Tran, Thang N ^a,b   Brettingham Moore, Kate ^a   Duong, Cuong P ^a,b   Mitchell, Catherine ^a   Clemons, Nicholas J ^a,b   Phillips, Wayne A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

gene amplification; mutation; PIK3CA; PTEN; tissue microarray

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; COPY NUMBER VARIATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STOMACH CANCER;

GENE AMPLIFICATION; MUTATION; PIK3CA; PTEN; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880268759     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23357     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, et al.: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Paoletti X, Oba K, Burzykowski T, et al.: Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. JAMA 2010; 303: 1729-1737.
3. Arkenau HT:, Gastric cancer in the era of molecularly targeted agents: Current drug development strategies. J Cancer Res Clin Oncol 2009; 135: 855-866.
4. Bader AG, Kang S, Zhao L, et al.: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921-929. (Pubitemid 41766781)
5. Samuels Y, Wang Z, Bardelli A, et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
6. Campbell IG, Russell SE, Choong DY, et al.: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-7681. (Pubitemid 39446895)
7. Philp AJ, Campbell IG, Leet C, et al.: The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumours. Cancer Res 2001; 61: 7426-7429. (Pubitemid 32995029)
8. Sheppard K, Kinross KM, Solomon B, et al.: Targeting PI3 kinase/AKT/mTOR signalling in cancer. Crit Rev Oncog 2012; 17: 69-95.
9. Byun DS, Cho K, Ryu BK, et al.: Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003; 104: 318-327. (Pubitemid 36249814)
10. Kim MS, Jeong EG, Yoo NJ, et al.: Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008; 98: 1533-1535. (Pubitemid 351652321)
11. Lee JW, Soung YH, Kim SY, et al.: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24: 1477-1480. (Pubitemid 40343128)
12. Li VS, Wong CW, Chan TL, et al.: Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005; 5: 29.
13. Velho S, Oliveira C, Ferreira A, et al.: The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41: 1649-1654. (Pubitemid 40981849)
14. den Dunnen JT, Antonarakis SE:, Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Hum Mutat 2000; 15: 7-12. (Pubitemid 30036162)
15. Waterworth A, Hanby A, Speirs V:, A novel cell array technique for high-throughput, cell-based analysis. In Vitro Cell Dev Biol Anim 2005; 41: 185-187. (Pubitemid 41504521)
16. Chou TC:, Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681. (Pubitemid 44403686)
17. Greene FJ, Page DL, Fleming ID, et al.: AJCC cancer staging manual, 6th edition. New York: Springer; 2002.
18. Campbell IG, Russell SE, Phillips WA:, PIK3CA mutations in ovarian cancer. Clin Cancer Res 2005; 11: 7042.
19. Qiu W, Schonleben F, Li X, et al.: PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 1441-1446.
20. Broderick DK, Di C, Parrett TJ, et al.: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas and medulloblastomas. Cancer Res 2004; 64: 5048-5050. (Pubitemid 39006515)
21. Hayes MP, Wang H, Espinal-Witter R, et al.: PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006; 12: 5932-5935. (Pubitemid 44703751)
22. Nakayama K, Nakayama N, Kurman RJ, et al.: Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 2006; 5: 779-785. (Pubitemid 44775134)
23. Oda K, Stokoe D, Taketani Y, et al.: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005; 65: 10669-10673. (Pubitemid 41713332)
24. Barbi S, Cataldo I, De Manzoni G, et al.: The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 2010; 29: 32.
25. Carpten JD, Faber AL, Horn C, et al.: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439-444. (Pubitemid 47123510)
26. Shoji K, Oda K, Nakagawa S, et al.: The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 2009; 101: 145-148.
27. Soung YH, Lee JW, Nam SW, et al.: Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006; 70: 285-289.
28. Chalhoub N, Baker SJ:, PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4: 127-150.
29. Vanhaesebroeck B, Stephens L, Hawkins P:, PI3K signalling: The path to discovery and understanding. Nat Rev Mol Cell Biol 2012; 13: 195-203.
30. Bae IH, Kang SW, Yoon SH, et al.: Cellular components involved in the cell death induced by cisplatin in the absence of p53 activation. Oncol Rep 2006; 15: 1175-1180.
31. Goto A, Shomori K, Ohkumo T, et al.: Hyperthermia-induced apoptosis occurs both in a p53 gene-dependent and -independent manner in three human gastric carcinoma cell lines. Oncol Rep 1999; 6: 335-339.
32. Shin JY, Kim JO, Lee SK, et al.: LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 2010; 10: 425.
33. Suvasini R, Somasundaram K:, Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy. Oncogene 2010; 29: 3605-3618.
34. Xing CG, Zhu BS, Liu HH, et al.: LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells. Acta Pharmacol Sin 2008; 29: 489-498.
35. Granville CA, Memmott RM, Gills JJ, et al.: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006; 12: 679-689. (Pubitemid 43259846)
36. Semba S, Itoh N, Ito M, et al.: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. Clin Cancer Res 2002; 8: 1957-1963. (Pubitemid 34633759)